Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MXCT vs DCGO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCGO Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–5 Matrix Metrics)

DCGO Overall Winner 6-Pillar Tally: MXCT 1 – 5 DCGO Matrix Metrics: MXCT 5 – 5 DCGO

As of Nov 20, 2026, DocGo Inc. (DCGO) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas DCGO carries 44.8/100 (HOLD) at $0.17 (60.2x Forward P/E, -29.0% operating margin).

  • Growth vs. Quality Trade-Off: DCGO earns the overall head-to-head edge with a stronger Unified Composite Score (44.8/100 HOLD vs. MXCT 41.7/100 SELL) and 1.35β · 108% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile DCGO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MXCT vs DCGO
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25
DCGO NASDAQ Head-to-Head Winner
DocGo Inc. Common Stock
Services-Health Services
$0.17
+1.98% 1D
Market Cap $17.0M
TTM Revenue $297M
Forward P/E 60.2x
Beta / 30D Vol 1.35β · 108% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.2%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $0.23 · SMA50: $0.29

6-Pillar Scorecard Institutional Category Breakdown (MXCT 1 – 5 DCGO)

Columns: Metric · MXCT · DCGO
1. Valuation Multiples DCGO
Forward P/E N/M 60.2x
Trailing P/E N/M 60.2x
PEG Ratio N/M N/M
EV / Revenue 3.9x 0.1x
2. Growth & Scale MXCT
Revenue Growth (YoY) +48.7% +3.7%
Earnings Growth (YoY) +0.0% +9.0%
TTM Revenue (USD) $34M $297M
Market Cap $132.2M $17.0M
3. Profitability & Quality DCGO
Gross Margin 81.0% 32.0%
Operating Margin -85.5% -29.0%
Net Profit Margin -81.4% -61.0%
Return on Equity (ROE) -16.9% -115.0%
4. Balance Sheet & Cash Flow DCGO
Cash Generation (TTM) -$24M -$29M
Cash Flow Margin -69.2% -9.6%
Net Cash / Leverage $2.2M Net Debt (0.11x D/E) $672,808 Net Debt (0.22x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCGO
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 0.2% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat DCGO
OpEx & R&D Intensity N/A 61.0% of Rev ($181M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MXCT (5) vs DCGO (5)
Institutional Metric MXCT DCGO Criterion Row Edge
Market Capitalization
Scale
$132.2M $17.0M Larger Scale MXCT
Trailing P/E Ratio
Valuation
N/M 60.2x Lower Multiple DCGO
Forward P/E Ratio
Valuation
N/M 60.2x Lower Multiple DCGO
Revenue Growth (YoY)
Growth
+48.7% +3.7% Higher Growth MXCT
Operating Margin (TTM)
Profitability
-85.5% -29.0% Higher Margin DCGO
Net Profit Margin
Profitability
-81.4% -61.0% Higher Margin DCGO
Return on Equity (ROE)
Capital Efficiency
-16.9% -115.0% Higher ROE MXCT
52-Week Range Position
Momentum
63% ($1–$2) 1% ($0–$1) Stronger Trend MXCT
Beta / 30D Volatility
Risk Regime
1.19β · 96% Vol 1.35β · 108% Vol Lower Realized Risk MXCT
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 44.8 / 100 (HOLD) Higher Composite DCGO
Trailing 12M Revenue (USD)
Operating Scale
$34M $297M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
81.0% 32.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($2.2M Net Debt (0.11x D/E)) -$29M ($672,808 Net Debt (0.22x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MXCT +31.01 pp
MXCT: -4.2% · DCGO: -35.21%
3M Horizon MXCT +52.7 pp
MXCT: -1.44% · DCGO: -54.14%
6M Horizon MXCT +103.97 pp
MXCT: +31.73% · DCGO: -72.24%
1Y Horizon MXCT +61.53 pp
MXCT: -19.41% · DCGO: -80.94%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MXCT Revenue DCGO Revenue MXCT Op. Margin DCGO Op. Margin Margin Leader
FY2019 $10M N/A -93.7% N/A MXCT
FY2020 $20M $90M -71.6% -15.7% DCGO
FY2021 $20M $320M -84.3% 4.8% DCGO
FY2022 $30M $440M -95.2% 5.0% DCGO
FY2023 $20M $620M -247.7% 2.4% DCGO
FY2024 $20M $620M -230.5% 4.7% DCGO
FY2025 $20M $320M -247.6% -55.3% DCGO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DCGO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.2%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DCGO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DCGO Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $17.0M market capitalization and -29.0% operating margin.
OpEx & R&D Reinvestment 61.0% of Rev ($181M)
90D Engineering Disclosures 0 Published

Investor FAQ MXCT vs DCGO Key Questions & Quantitative Answers

As of Nov 20, 2026, DocGo Inc. (DCGO) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas DCGO carries 44.8/100 (HOLD) at $0.17 (60.2x Forward P/E, -29.0% operating margin). Growth vs. Quality Trade-Off: DCGO earns the overall head-to-head edge with a stronger Unified Composite Score (44.8/100 HOLD vs. MXCT 41.7/100 SELL) and 1.35β · 108% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile DCGO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MXCT leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with DCGO at +3.7% YoY revenue growth and +9.0% YoY earnings growth on $297M TTM revenue (32.0% gross margin, -29.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), MXCT cumulative revenue shifted +100.0% while DCGO shifted +255.6%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus 61.0% of Rev ($181M) (0 disclosures) for DCGO.

DCGO screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas DCGO trades at 60.2x Forward P/E, 60.2x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-9.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus DCGO (-115.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, DCGO carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 108% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.